These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25051350)

  • 1. Silencing of CXCR7 gene represses growth and invasion and induces apoptosis in colorectal cancer through ERK and β-arrestin pathways.
    Li XX; Zheng HT; Huang LY; Shi DB; Peng JJ; Liang L; Cai SJ
    Int J Oncol; 2014 Oct; 45(4):1649-57. PubMed ID: 25051350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of CXCR7 inhibits proliferation and invasion of osteosarcoma cells through inhibition of the PI3K/Akt and β-arrestin pathways.
    Zhang Y; Yang CQ; Gao Y; Wang C; Zhang CL; Zhou XH
    Oncol Rep; 2014 Sep; 32(3):965-72. PubMed ID: 24969680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KNOCKDOWN OF CASEIN KINASE 1e INHIBITS CELL PROLIFERATION AND INVASION OF COLORECTAL CANCER CELLS VIA INHIBITION OF THE Wnt/β-CATENIN SIGNALING.
    Ye LC; Jiang C; Bai J; Jiang J; Hong HF; Qiu LS
    J Biol Regul Homeost Agents; 2015; 29(2):307-15. PubMed ID: 26122218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging ligand-dependent activation of CXCR7.
    Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
    Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
    Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
    J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
    Qiao N; Wang L; Wang T; Li H
    Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR7/CXCL12 axis is involved in lymph node and liver metastasis of gastric carcinoma.
    Xin Q; Zhang N; Yu HB; Zhang Q; Cui YF; Zhang CS; Ma Z; Yang Y; Liu W
    World J Gastroenterol; 2017 May; 23(17):3053-3065. PubMed ID: 28533662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation.
    Salazar N; Muñoz D; Kallifatidis G; Singh RK; Jordà M; Lokeshwar BL
    Mol Cancer; 2014 Aug; 13():198. PubMed ID: 25168820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of CXCR4 and CXCR7 for reduction of cell proliferation and invasion in human endometrial cancer.
    Long P; Sun F; Ma Y; Huang Y
    Tumour Biol; 2016 Jun; 37(6):7473-80. PubMed ID: 26678890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells.
    Zhen Y; Guanghui L; Xiefu Z
    Cancer Gene Ther; 2014 Nov; 21(11):491-7. PubMed ID: 25394504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of stat4 gene inhibits cell proliferation and invasion of colorectal cancer cells.
    Cheng JM; Yao MR; Zhu Q; Wu XY; Zhou J; Tan WL; Zhan SH
    J Biol Regul Homeost Agents; 2015; 29(1):85-92. PubMed ID: 25864744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LPS-induced CXCR7 expression promotes gastric Cancer proliferation and migration via the TLR4/MD-2 pathway.
    Li N; Xu H; Ou Y; Feng Z; Zhang Q; Zhu Q; Cai Z
    Diagn Pathol; 2019 Jan; 14(1):3. PubMed ID: 30636642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma.
    Xu H; Wu Q; Dang S; Jin M; Xu J; Cheng Y; Pan M; Wu Y; Zhang C; Zhang Y
    PLoS One; 2011; 6(12):e27399. PubMed ID: 22180778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway.
    Miao JH; Wang SQ; Zhang MH; Yu FB; Zhang L; Yu ZX; Kuang Y
    Oncol Rep; 2014 Oct; 32(4):1497-504. PubMed ID: 25069486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ShRNA knock-down of CXCR7 inhibits tumour invasion and metastasis in hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Zhao ZW; Fan XX; Song JJ; Xu M; Chen MJ; Tu JF; Wu FZ; Zhang DK; Liu L; Chen L; Ying XH; Ji JS
    J Cell Mol Med; 2017 Sep; 21(9):1989-1999. PubMed ID: 28429395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
    Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
    Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR7 expression correlates with tumor depth in cutaneous squamous cell carcinoma skin lesions and promotes tumor cell survival through ERK activation.
    Hu SC; Yu HS; Yen FL; Chen GS; Lan CC
    Exp Dermatol; 2014 Dec; 23(12):902-8. PubMed ID: 25256412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR7 as a chemokine receptor for SDF-1 promotes gastric cancer progression via MAPK pathways.
    Shi A; Shi H; Dong L; Xu S; Jia M; Guo X; Wang T
    Scand J Gastroenterol; 2017; 52(6-7):745-753. PubMed ID: 28281844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Abnormal expression of APRIL in colorectal cancer cells promotes tumor growth and metastasis].
    Wang GH; Lu MH; Wang JC; Wang F; Ding WF; Wang YG; Ju SQ; Wang HM
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):249-55. PubMed ID: 23985251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulated NNT-AS1, a long noncoding RNA, contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo.
    Wang Q; Yang L; Hu X; Jiang Y; Hu Y; Liu Z; Liu J; Wen T; Ma Y; An G; Feng G
    Oncotarget; 2017 Jan; 8(2):3441-3453. PubMed ID: 27966450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.